Who
Herriot Tabuteau
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Axsome Therapeutics.
In numbers
- Trades disclosed
- 108
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $174.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Nov 2015
- Last trade
- 6 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $23K4,660 at $4.95 | filing |
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,660 at $0.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $997K4,660 at $213.95 | filing |
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,660 at $0.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $23K4,660 at $4.95 | filing |
| 6 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $997K4,660 at $213.95 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $223K45,004 at $4.95 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.5M45,004 at $212.01 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,004 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,004 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $223K45,004 at $4.95 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.5M45,004 at $212.01 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $246K49,666 at $4.95 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $11.9M49,666 at $240.25 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,666 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,666 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $246K49,666 at $4.95 | filing |
| 1 Jul 2026filed 1 Jul 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $11.9M49,666 at $240.25 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $246K49,670 at $4.95 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $12.0M49,670 at $241.01 | filing |
News
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?AXSM · insidermonkey.com · 13 Oct 2026Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?AXSM · fool.com · 12 Oct 2026
0 headlines in the last 90 days name Herriot Tabuteau; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.